US Stock MarketDetailed Quotes
GLTO Galecto
- 5.620
- -0.225-3.85%
Close Nov 22 16:00 ET
7.40MMarket Cap-294P/E (TTM)
6.190High5.520Low37.03KVolume5.940Open5.845Pre Close217.54KTurnover3.05%Turnover RatioLossP/E (Static)1.32MShares23.50052wk High0.35P/B6.82MFloat Cap5.52052wk Low--Dividend TTM1.21MShs Float449.750Historical High--Div YieldTTM11.46%Amplitude5.520Historical Low5.875Avg Price1Lot Size
About Galecto Company
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf J?rgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsg?rd Schambye in 2011 and is headquartered in Boston, MA.
Company Profile
SymbolGLTO
Company NameGalecto
Listing DateOct 29, 2020
Issue Price15.00
Founded2011
CEODr. Hans T. Schambye, M.D.,PhD
MarketNASDAQ
Employees13
Fiscal Year Ends12-31
Address75 State Street,Suite 100
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02109
Phone1-45-070-5210
Websitehttp://www.galecto.com
Company Executives
- Name
- Position
- Salary
- Dr. Hans T. Schambye, M.D.,PhD
- Director, President and Chief Executive Officer
- 965.12K
- Jonathan Freve
- Chief Financial Officer and Principal Accounting Officer
- 701.33K
- Dr. Carl S. Goldfischer,M.D.
- Chairman of the Board
- 155.19K
- Dr. Soren Moller, PhD
- Independent Director
- --
- Dr. Amy B. Wechsler, M.D.
- Independent Director
- --
- Dr. Jayson Dallas, M.D.
- Independent Director
- 86.35K
- Dr. David Shapiro, M.D.
- Independent Director
- 148.84K
- Amit D. Munshi
- Independent Director
- 78.85K
- Dr. Anne Prener, M.D.,PhD
- Independent Director
- 83.85K
- Garrett Winslow
- General Counsel and Corporate Secretary
- 554.39K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data